$EYEN News
Last published 1y ago
- 1y agoEYENSydnexis, Inc. vs Eyenovia, Inc. - AIA Trial, AffirmedUS Patent Trial and Appeal Board
- 1y agoEYENSydnexis, Inc. vs Eyenovia, Inc. - AIA Trial, AffirmedUS Patent Trial and Appeal Board
- 1y agoEYENSydnexis, Inc. vs Eyenovia, Inc. - AIA Trial, AffirmedUS Patent Trial and Appeal Board
- 1y agoEYENEyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.GlobeNewswireName change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol "HYPD" effective July 3rd Also
- 1y agoEYENEyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain EngagementGlobeNewswireLAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic
- 1y agoEYENEyenovia Announces Co-Branded Validator with KinetiqGlobeNewswireLAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic
- 1y agoEYENLGHLVVPRKIDZChardan Expands into Digital Assets by Advising Strategic Crypto-Backed FinancingsPR NewswireChardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and...
- 1y agoEYENEyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital GroupGlobeNewswireLAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic
- 1y agoEYENEyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve StrategyGlobeNewswireAnnounces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS, Calif., June 17, 2025
- 1y agoAVAIBLCOBMEAEYEN+1Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue OpportunitiesGlobeNewswirePALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus
- 1y agoEYENEyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial ResultsGlobeNewswireEyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and
- 1y agoEYENEyenovia Provides Development Update on Optejet User Filled Device (UFD)GlobeNewswireNEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary
- 1y agoEYENEyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with BetaliqGlobeNewswireCombination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® device platform The
- 1y agoEYENEyenovia Regains Compliance with All Nasdaq Continued Listing RequirementsGlobeNewswireNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device,
- 1y agoEYENEyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic AlternativesGlobeNewswireNEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today
- 1y agoEYENEyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing DeviceGlobeNewswireNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today
- 1y agoEYENEyenovia Announces 1-for-80 Reverse Stock SplitGlobeNewswireNEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic
- 1y agoEYENEyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote "FOR" Proposed Reverse Stock Split at Upcoming Special Meeting of StockholdersGlobeNewswireNEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company, today announced that the two leading independent proxy advisory firms,
- 1y agoEYENEyenovia Engages Chardan as Advisor for Review of Strategic AlternativesGlobeNewswireNEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic
- 1y agoEYENEyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct OfferingGlobeNewswireNEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary
- 1y agoEYENEyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct OfferingGlobeNewswireNEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary
- 1y agoEYENEyenovia Provides Update on Restructuring EffortsGlobeNewswireAvenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic alternatives to maximize
- 1y agoEYENEyenovia Provides Update on Phase 3 CHAPERONE StudyGlobeNewswireA review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and evaluate next steps for
- 1y agoEYENEyenovia, Inc. (EYEN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoEYENEyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireAdvanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its
- 2y agoEYENEyenovia to Report Third Quarter 2024 Results on Tuesday, November 12thGlobeNewswireNEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic
- 2y agoEYENEyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®GlobeNewswirePublication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives Additional
- 2y agoEYENEyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 ExpoGlobeNewswireNEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, which is being held
- 2y agoEYENEyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet DeviceGlobeNewswireNEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of its FDA-approved
- 2y agoEYENEyenovia, Inc. Announces Pricing of $4 Million Registered Direct OfferingGlobeNewswireNEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the
- 2y agoEYENEyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular SurgeryGlobeNewswireNEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company, today announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension
- 2y agoEYENFormosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for CommercializationPR NewswireFormosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of...
- 2y agoEYENEyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.GlobeNewswireNEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric
- 2y agoEYENEyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial OfficerGlobeNewswireNEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced
- 2y agoEYENEyenovia Announces Closing of Public OfferingGlobeNewswireNEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ:EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of
- 2y agoEYENEyenovia Announces Pricing of $5.14 Million Public OfferingGlobeNewswireNEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ:EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common
- 2y agoEYENEyenovia, Inc. Announces Proposed Public OfferingGlobeNewswireNEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ:EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell shares of its common
- 2y agoEYENEyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceGlobeNewswireNEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for
- 2y agoEYENEyenovia, Inc. (EYEN) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoEYENEyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireFollowing FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a
- 2y agoEYENEyenovia to Report Second Quarter 2024 Results on Monday, August 12thGlobeNewswireNEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company
- 2y agoEYENEyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.GlobeNewswireNEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced
- 2y agoEYENFormosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United StatesPR NewswireTaiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia,...
- 2y agoEYENEyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye DiseaseGlobeNewswireNEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, and SGN Nanopharma,
- 2y agoEYENEyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye DiseaseGlobeNewswireCollaboration to focus on the development of a formulation of Senju's SJP-0035 for use with Eyenovia's Optejet® dispensing technology, following consultation with FDA Chronic dry eye estimated to be a $5 billion
- 2y agoEYENNBYNovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion ActivitiesBusiness WirePartnership co-promoting NovaBay's Avenova® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia's FDA-approved product MydCombi™ Preparing for
- 2y agoEYENEyenovia Announces Pricing of $5M Registered Direct OfferingGlobeNewswireNEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ:EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement
- 2y agoEYENEyenovia, Inc. (EYEN) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoEYENEyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and ClobetasolGlobeNewswireRemains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the first new ophthalmic
- 2y agoEYENEyenovia to Report First Quarter 2024 Results on Wednesday, May 15thGlobeNewswireNEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company